A Phase 3 interventional study of Ibrutinib and Temsirolimus in Mantle Cell Lymphoma, sponsored by Janssen Research & Development, LLC. Completed at 98 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-01-19.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies testing ibrutinib in Lymphoma, Mantle-Cell — 2 open to participants now, 16 under way, 2 of them phase 3. ibrutinib · Lymphoma, Mantle-Cell.
Among the 45 studies testing ibrutinib in Lymphoma, Mantle-Cell, this one is the 4th largest by enrollment, is one of 2 that started in 2012, is one of 6 in phase 3, and was the 6th registered.
1,223 studies on the registry are indexed under Lymphoma, Mantle-Cell; 156 are open to participants now.
Browse Lymphoma, Mantle-Cell studies →2 of the 45 studies testing ibrutinib in Lymphoma, Mantle-Cell are open now, in 6 countries. Recruiting first, the newest first:
OHSU Knight Cancer Institute · Sites in United States
Ages 18+
Prof. Dr. M. Dreyling (co-chairman) · Sites in Denmark, Germany, Italy and 2 more countries
Ages 18–65
By country, each count listing its studies:
ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 93 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 26 · Phase 3 6 · Phase 4 1
First in 2009; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 280 is above the median of 37 across 1,003 interventional studies indexed under Lymphoma, Mantle-Cell.
Median enrollment 39 across the 45 interventional studies. Of the 24 that completed or were terminated, 12 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 45 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 933 studies on the registry; 77 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
16 studies in Lymphoma, Mantle-Cell by Johnson & Johnson: none open now, 1 under way, 1 of them phase 3. Of 13 finished, 5 (38%) have results posted.
Among the 16 studies in Lymphoma, Mantle-Cell by Johnson & Johnson, this one is the 3rd largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2012, is one of 3 in phase 3, and was the 3rd registered.
Johnson & Johnson’s Lymphoma, Mantle-Cell studies by the year they started, since 2012.
6 of the studies testing ibrutinib in Lymphoma, Mantle-Cell that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT01479842Kami Maddocks, MDRituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma | 2026-12-01 |
| NCT03710772M.D. Anderson Cancer CenterIbrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma | 2027-03-22 |
| NCT03153202Joshua BrodyStudy to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) | 2027-04 |
| NCT02427620M.D. Anderson Cancer CenterIbrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 45 studies testing ibrutinib in Lymphoma, Mantle-Cell, from their registry updates:
Among Johnson & Johnson’s 16 in Lymphoma, Mantle-Cell:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of ibrutinib versus temsirolimus in patients with relapsed or refractory mantle cell lymphoma who received at least 1 prior chemotherapy regimen.
This is a randomized (individuals assigned to study treatment by chance), open-label (identity of assigned study drug will be known), study to evaluate the efficacy and safety of ibrutinib when compared with temsirolimus in patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least 1 prior rituximab-containing chemotherapy regimen. Approximately 280 eligible patients will be randomly assigned in a 1:1 ratio and stratified (grouped) by the number of prior lines of therapy (1 or 2 versus >=3) and simplified MCL International Prognostic Index criteria to receive either ibrutinib by mouth (Treatment Arm A) or temsirolimus intravenous infusion (Treatment Arm B). The study will consist of screening, treatment, and posttreatment phases. Data will be collected on disease response to the treatment, progression-free survival, overall survival, subsequent anti-MCL therapies, patient reported outcomes, and medical resource utilization. Tumor samples, blood collected at multiple time points, and a bone marrow aspirate will be evaluated to identify markers predictive of response or resistance to ibrutinib. Serial pharmacokinetic (study of what the body does to a drug) samples will be collected as detailed in the protocol. Safety will be monitored throughout the study. Disease evaluations will be performed every 9 weeks for up to 15 months from the start of study drug, and every 24 weeks thereafter, until disease progression, death, or the clinical cutoff, whichever comes first. Patients who receive treatment with temsirolimus and have disease progression (confirmed by an Independent Review Committee) may be eligible to crossover and receive treatment with ibrutinib 560 mg orally, daily, on a 21-day cycle until disease progression, unacceptable toxicity, or study end. Data will be analyzed up to 3 years after the last patient is enrolled for the final follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Ibrutinib
Drug: Temsirolimus
560 mg once daily continuous (without interruption) by mouth for 21-day cycles
175 mg once daily intravenous infusion on Days 1, 8, 15 of the first cycle followed by 75 mg on Days 1, 8, 15 of each 21-day cycle
Progression Free Survival (PFS)
PFS is defined as the duration in months from the date of randomization to the date of progression disease (PD) or relapse from complete response (CR) or death whichever was reported first and was assessed based on the investigator assessment. Revised Response Criteria for Malignant Lymphoma categorizes the response of the treatment of a patient's tumour to CR (the disappearance of all evidence of disease), Relapsed Disease or PD (Any new lesion or increase by greater than or equal to \[\>=\] 50 percent \[%\] of previously involved sites from nadir).
Time frame: Time from the date of randomization until the date of first documented evidence of progressive disease (or relapse for subjects who experience CR during the study) or death, whichever occurred first (approximately 48 months)
Overall Response Rate (ORR)
ORR is defined as the percentage of participants who achieved either CR or PR as best overall response based on the investigator assessment. CR is Disappearance of all target lesions while PR is greater than or equal to 30 % decrease in the sum of the longest diameter of target lesions and Overall Response (OR) is sum of CR and PR.
Time frame: Approximately up to 48 months
Overall Survival (OS)
Overall survival (OS) was defined as the interval between the date of randomization and the date of death from any cause.
Time frame: Approximately up to 48 months
Duration of Response
Duration of response (CR or PR), defined as the duration in days from the date of initial response to the date of first documented evidence of progressive disease (or relapse for participants who experience CR during the study) or death. The analysis was based on the investigator assessment.
Time frame: Approximately up to 48 months
Time-to-Next Treatment
Time to next treatment was measured from the date of randomization to the start date of any anti-neoplastic treatment subsequent to study treatment.
Time frame: Approximately up to 48 months
Progression-Free Survival 2
Progression-free survival 2 defined as the time interval between the date of randomization and date of event, defined as progressive disease as assessed by investigator that started after the next line of subsequent anti-neoplastic therapy (including cross-over to ibrutinib), death from any cause, or the start of the second subsequent anti-neoplastic therapy if no progressive disease was recorded after the first subsequent anti-neoplastic therapy.
Time frame: Approximately up to 48 months
Time to Worsening in the Lymphoma Sub Scale of Functional Assessment of Cancer Therapy- Lymphoma (FACT-Lym)
Time to worsening in the Lymphoma subscale of the FACT-Lym, defined as the interval from the date of randomization to the start date of worsening. Worsening was defined by a 5-point decrease from baseline. FACT-Lym Lymphoma subscale contains 15 questions, scores from 0 to 4 for each question (higher the worse). Lymphoma subscale score is the total of reverse scores, range 0 to 60. Higher scores indicate a better quality of life.
Time frame: Approximately up to 48 months
Number of Participants Affected With Treatment-emergent Adverse Events
An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Time frame: Time from first dose of study drug until the last dose date + 30 days or the start of a subsequent anti-neoplastic therapy, whichever occur earlier (Approximately up to 4 years)
Time to Response
Time to response for participants with CR/PR, defined as the interval between the date of randomization and date of initial documentation of response.
Time frame: Approximately up to 2.8 years
Extent of Exposure of Time
Extent of exposure is defined as the duration of the treatment administered during the study. Duration of exposure is calculated as the number of months between the start and end of treatment.
Time frame: Approximately up to 46.8 months
One Year Survival Rate
One -year survival rate, defined as the proportion of participants who were alive 1 year after randomization.
Time frame: Month 12
Area Under the Plasma Concentration of Ibrutinib During Steady State (AUC-ss)
The AUC-ss is the area under the plasma concentration time curve observed during steady state.
Time frame: Cycle 1 and 2 (Day 1): Predose, 1, 2, 4 hr. postdose; Cycle 3 (day 1): Predose (Each cycle is of 21 days)
Number of Participants With Biomarkers That Alter B-cell Receptor (BCR) Signaling or Activate Alternative Signaling Pathways and to Explore Their Association With Response or Resistance to Ibrutinib
Biomarker evaluations to identify markers altering BCR signaling or activate alternative signaling pathways and explore their association with response or resistance to ibrutinib. Next-generation sequencing at baseline identifies possible primary resistance mutations and those found only at progression are acquired mutations on therapy.
Time frame: Approximately up to 28.2 months
Number of Hospitalizations Reported Related Medical Resource Utilization Information (MRUI)
Medical resource utilization data associated with medical encounters related to disease was reported for all participants throughout the study.
Time frame: Approximately up to 28.2 months
Number of Emergency Room Visits Reported Related Medical Resource Utilization Information (MRUI)
Medical resource utilization data associated with medical encounters related to disease was reported for all participants throughout the study.
Time frame: Approximately up to 28.2 months
Days of Hospitalization and Emergency Room Visits Reported Related Medical Resource Utilization Information (MRUI)
Medical resource utilization data associated with medical encounters related to disease was reported for all participants throughout the study.
Time frame: Approximately up to 28.2 months
The Mean Change From Baseline in Euro QoL Five-Dimension (EQ-5D-5L) Scores for Each Post Baseline Assessment
The EQ-5D is a participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression, using 5 levels (1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and possible total score range -0.594 to 1; higher score indicates a better health state.
Time frame: Baseline, Cycle 2, 3, 4, 5, 6, 7, 8, 11, 14, 17, 20, 28, 36 and End of treatment (approximately up to 23 months)
| Milestone | Ibrutinib | Temsirolimus |
|---|---|---|
| Started | 139 | 141 |
| Treated | 139 | 139 |
| Completed | 0 | 0 |
| Not completed | 139 | 141 |
| Withdrew: Death | 77 | 83 |
| Withdrew: Study terminated by sponsor | 50 | 41 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Withdrawal by subject | 10 | 15 |
PFS is defined as the duration in months from the date of randomization to the date of progression disease (PD) or relapse from complete response (CR) or death whichever was reported first and was assessed based on the investigator assessment. Revised Response Criteria for Malignant Lymphoma categorizes the response of the treatment of a patient's tumour to CR (the disappearance of all evidence of disease), Relapsed Disease or PD (Any new lesion or increase by greater than or equal to \[\>=\] 50 percent \[%\] of previously involved sites from nadir).
| Months | Ibrutinib | Temsirolimus |
|---|---|---|
| Progression Free Survival (PFS) | 15.6 (10.6 to 25.1) | 6.2 (4.2 to 7.8) |
ORR is defined as the percentage of participants who achieved either CR or PR as best overall response based on the investigator assessment. CR is Disappearance of all target lesions while PR is greater than or equal to 30 % decrease in the sum of the longest diameter of target lesions and Overall Response (OR) is sum of CR and PR.
| Percentage of participants | Ibrutinib | Temsirolimus |
|---|---|---|
| Overall Response Rate (ORR) | 77.0 | 46.8 |
Overall survival (OS) was defined as the interval between the date of randomization and the date of death from any cause.
| Months | Ibrutinib | Temsirolimus |
|---|---|---|
| Overall Survival (OS) | 30.3 (19.1 to 42.1) | 23.5 (13.0 to 30.7) |
Duration of response (CR or PR), defined as the duration in days from the date of initial response to the date of first documented evidence of progressive disease (or relapse for participants who experience CR during the study) or death. The analysis was based on the investigator assessment.
| Months | Ibrutinib | Temsirolimus |
|---|---|---|
| Duration of Response | 23.1 (16.2 to 28.1) | 6.3 (4.7 to 8.6) |
Time to next treatment was measured from the date of randomization to the start date of any anti-neoplastic treatment subsequent to study treatment.
| Months | Ibrutinib | Temsirolimus |
|---|---|---|
| Time-to-Next Treatment | 31.8 (23.3 to NA) | 11.6 (8.0 to 13.3) |
Progression-free survival 2 defined as the time interval between the date of randomization and date of event, defined as progressive disease as assessed by investigator that started after the next line of subsequent anti-neoplastic therapy (including cross-over to ibrutinib), death from any cause, or the start of the second subsequent anti-neoplastic therapy if no progressive disease was recorded after the first subsequent anti-neoplastic therapy.
| Months | Ibrutinib | Temsirolimus |
|---|---|---|
| Progression-Free Survival 2 | 26.2 (17.2 to 32.4) | 15.4 (10.2 to 21.3) |
Time to worsening in the Lymphoma subscale of the FACT-Lym, defined as the interval from the date of randomization to the start date of worsening. Worsening was defined by a 5-point decrease from baseline. FACT-Lym Lymphoma subscale contains 15 questions, scores from 0 to 4 for each question (higher the worse). Lymphoma subscale score is the total of reverse scores, range 0 to 60. Higher scores indicate a better quality of life.
| Weeks | Ibrutinib | Temsirolimus |
|---|---|---|
| Time to Worsening in the Lymphoma Sub Scale of Functional Assessment of Cancer Therapy- Lymphoma (FACT-Lym) | NA (81.4 to NA) | 10.6 (6.6 to 15.3) |
An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
| Participants | Ibrutinib | Temsirolimus |
|---|---|---|
| Number of Participants Affected With Treatment-emergent Adverse Events | 139 | 138 |
Time to response for participants with CR/PR, defined as the interval between the date of randomization and date of initial documentation of response.
| Months | Ibrutinib | Temsirolimus |
|---|---|---|
| Time to Response | 2.15 (0.5 to 10.4) | 2.14 (0.9 to 12.0) |
Extent of exposure is defined as the duration of the treatment administered during the study. Duration of exposure is calculated as the number of months between the start and end of treatment.
| Months | Ibrutinib | Temsirolimus |
|---|---|---|
| Extent of Exposure of Time | 14.39 (0.0 to 46.8) | 3.02 (0.0 to 31.4) |
One -year survival rate, defined as the proportion of participants who were alive 1 year after randomization.
| Proportion of participants | Ibrutinib | Temsirolimus |
|---|---|---|
| One Year Survival Rate | 0.68 (0.59 to 0.75) | 0.61 (0.52 to 0.69) |
The AUC-ss is the area under the plasma concentration time curve observed during steady state.
| nanogram*hour per milliliter (ng*h/mL) | Ibrutinib |
|---|---|
| Area Under the Plasma Concentration of Ibrutinib During Steady State (AUC-ss) | 561.6 ± 448 |
Biomarker evaluations to identify markers altering BCR signaling or activate alternative signaling pathways and explore their association with response or resistance to ibrutinib. Next-generation sequencing at baseline identifies possible primary resistance mutations and those found only at progression are acquired mutations on therapy.
| Participants | Ibrutinib | Temsirolimus |
|---|---|---|
| Number of Participants With Biomarkers That Alter B-cell Receptor (BCR) Signaling or Activate Alternative Signaling Pathways and to Explore Their Association With Response or Resistance to Ibrutinib | 61 | 53 |
Medical resource utilization data associated with medical encounters related to disease was reported for all participants throughout the study.
| Hospitalizations | Ibrutinib | Temsirolimus |
|---|---|---|
| Number of Hospitalizations Reported Related Medical Resource Utilization Information (MRUI) | 3.1 ± 4.6 | 2.8 ± 4.3 |
Medical resource utilization data associated with medical encounters related to disease was reported for all participants throughout the study.
| Emergency room visits | Ibrutinib | Temsirolimus |
|---|---|---|
| Number of Emergency Room Visits Reported Related Medical Resource Utilization Information (MRUI) | 1.2 ± 0.4 | 1.2 ± 0.4 |
Medical resource utilization data associated with medical encounters related to disease was reported for all participants throughout the study.
| Days | Ibrutinib | Temsirolimus |
|---|---|---|
| Mean days of hospitalization | 19.7 ± 20.5 | 20.3 ± 22.4 |
| Mean days of emergency room visits | 1.8 ± 1.3 | 1.6 ± 1.3 |
The EQ-5D is a participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression, using 5 levels (1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and possible total score range -0.594 to 1; higher score indicates a better health state.
| Units on scale | Ibrutinib | Temsirolimus |
|---|---|---|
| Baseline | 0.7 ± 0.2 | 0.7 ± 0.2 |
| Change at Cycle 2 | 0.0 ± 0.2 | 0.0 ± 0.2 |
| Change at Cycle 3 | 0.1 ± 0.2 | -0.1 ± 0.2 |
| Change at Cycle 4 | 0.0 ± 0.2 | 0.0 ± 0.3 |
| Change at Cycle 5 | 0.0 ± 0.2 | 0.0 ± 0.2 |
| Change at Cycle 6 | 0.1 ± 0.2 | 0.0 ± 0.2 |
| Change at Cycle 7 | 0.0 ± 0.2 | 0.0 ± 0.2 |
| Change at Cycle 8 | 0.0 ± 0.2 | 0.0 ± 0.2 |
| Change at Cycle 11 | 0.0 ± 0.2 | 0.0 ± 0.2 |
| Change at Cycle 14 | 0.0 ± 0.2 | 0.0 ± 0.1 |
| Change at Cycle 17 | 0.0 ± 0.2 | 0.0 ± 0.2 |
| Change at Cycle 20 | 0.0 ± 0.2 | 0.0 ± 0.2 |
| Change at Cycle 28 | -0.1 ± 0.2 | 0.1 ± 0.2 |
| Change at Cycle 36 | 0.0 ± 0.3 | -0.1 ± 0.2 |
| Change at End of treatment | 0.0 ± 0.2 | -0.1 ± 0.3 |
Collected over Approximately up to 4 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ibrutinib | 130/139 (93.5%) | 79/139 (56.8%) | 130/139 (93.5%) |
| Temsirolimus | 137/139 (98.6%) | 83/139 (59.7%) | 137/139 (98.6%) |
| Event | Ibrutinib | Temsirolimus |
|---|---|---|
| PneumoniaInfections and infestations | 16/139 | 12/139 |
| Atrial FibrillationCardiac disorders | 7/139 | 2/139 |
| PyrexiaGeneral disorders | 3/139 | 7/139 |
| SepsisInfections and infestations | 6/139 | 5/139 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 6/139 | 5/139 |
| Pleural EffusionRespiratory, thoracic and mediastinal disorders | 6/139 | 0/139 |
| AnaemiaBlood and lymphatic system disorders | 4/139 | 5/139 |
| ThrombocytopeniaBlood and lymphatic system disorders | 5/139 | 3/139 |
| Abdominal PainGastrointestinal disorders | 5/139 | 1/139 |
| General Physical Health DeteriorationGeneral disorders | 3/139 | 5/139 |
| Event | Ibrutinib | Temsirolimus |
|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 25/139 | 77/139 |
| AnaemiaBlood and lymphatic system disorders | 27/139 | 57/139 |
| DiarrhoeaGastrointestinal disorders | 45/139 | 42/139 |
| FatigueGeneral disorders | 31/139 | 40/139 |
| NeutropeniaBlood and lymphatic system disorders | 21/139 | 36/139 |
| Oedema PeripheralGeneral disorders | 19/139 | 33/139 |
| CoughRespiratory, thoracic and mediastinal disorders | 31/139 | 31/139 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 13/139 | 31/139 |
| NauseaGastrointestinal disorders | 20/139 | 30/139 |
| StomatitisGastrointestinal disorders | 4/139 | 28/139 |
| Age, Categorical(Participants) | Ibrutinib | Temsirolimus | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 53 | 54 | 107 |
| >=65 years | 86 | 87 | 173 |
| Age, Continuous(years) | Ibrutinib | Temsirolimus | Total |
|---|---|---|---|
| Mean | 66.7 ± 8.68 | 67.1 ± 9.83 | 66.9 ± 9.26 |
| Sex/Gender, Customized(participants) | Ibrutinib | Temsirolimus | Total |
|---|---|---|---|
| Female | 39 | 33 | 72 |
| Male | 100 | 108 | 208 |
| Region of Enrollment(participants) | Ibrutinib | Temsirolimus | Total |
|---|---|---|---|
| Belgium | 7 | 10 | 17 |
| Brazil | 5 | 10 | 15 |
| Canada | 6 | 3 | 9 |
| Colombia | 3 | 4 | 7 |
| Czech Republic | 7 | 7 | 14 |
| Germany | 12 | 11 | 23 |
| Spain | 5 | 14 | 19 |
| France | 5 | 5 | 10 |
| United Kingdom | 11 | 16 | 27 |
| Hungary | 5 | 7 | 12 |
| Ireland | 2 | 1 | 3 |
| Italy | 6 | 8 | 14 |
| South Korea | 11 | 3 | 14 |
| Mexico | 1 | 1 | 2 |
| Netherlands | 2 | 0 | 2 |
| Poland | 9 | 14 | 23 |
| Portugal | 3 | 3 | 6 |
| Russian Federation | 18 | 11 | 29 |
| Sweden | 10 | 8 | 18 |
| Taiwan | 5 | 1 | 6 |
| Ukraine | 6 | 4 | 10 |
Ran from Dec 2012 to primary completion in Jun 2015, 29 months.
Results were first posted in Mar 2017, 1 year 8 months after primary completion.
Of 27 phase 3 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 97 months of starting (the median), counting those still running; a quarter within 68. This study's 29 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ibrutinib · Temsirolimus
Janssen Research & Development, LLC →